Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.6.2643

Human Papillomavirus Screening in North Indian Women  

Pandey, Saumya (Krishna Medical Center, Chhatrapati Shahuji Maharaj Medical University)
Mishra, Malvika (Krishna Medical Center, Chhatrapati Shahuji Maharaj Medical University)
Chandrawati, Chandrawati (Krishna Medical Center, Chhatrapati Shahuji Maharaj Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.6, 2012 , pp. 2643-2646 More about this Journal
Abstract
Objectives: Human papillomavirus (HPV) is the major etiological agent of cervical cancer, a leading cause of morbidity and mortality in women worldwide. Screening strategies for reducing the burden of HPV-mediated carcinogenesis are emerging as an effective means for cervical cancer control and prevention in developing countries. Our study, therefore, aimed to identify HPV infection status in North Indian women during random population screening. Methodology: Cervical/vaginal exfoliated cells and/or Pap smear specimens were collected from 890 women of North Indian ethnicity residing in Lucknow and adjoining areas, during random population screening from June 2009-March 2012. HPV viral loads in clinical specimens were determined by the Hybrid Capture (hc)-2 HPV DNA assay, and subsequently, positive/negative/borderline HPV status was calculated. Results: The HPV incidence in the present study was 11.7%. 751 out of a total of 890 women (84.4%) participating in our HPV screening program were HPV negative (HPV -), 104 (11.7%) tested positive (HPV +) while 35 (3.9%) showed borderline (HPV $^*$) infection status. Furthermore, in the HPV + subjects (N=104), 18 (17.3%) showed strong positivity. We observed that HPV positivity tends to increase with age in North Indian women; the higher the viral load with increasing age, higher is the susceptibility to HPV-mediated cervical cancer. Conclusions: HPV viral load/genotyping may help in identifying women at risk of developing cervical cancer. However, cost-effective HPV screening protocols with a wider population coverage are warranted so as to reduce the burden of cervical cancer in women worldwide in the vaccine-era.
Keywords
Cervical cancer; human papillomavirus; north India; screening; viral load;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364, 1757-65.   DOI
2 Harper DM, Franco EL, Wheeler C, et al (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367, 1247-55.   DOI
3 Hildesheim A, Schiffman MH, Gravitt PE, et al (1994). Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis, 169, 235-40.   DOI
4 International Agency for Research on Cancer (2005). IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. Lyon: IARC Press.
5 Jo H, Kim JW (1998). Implications of HPV infection in uterine cervical cancer. Sex Transm Inf, 74, 101-9.   DOI
6 Li TT, Zhao LN, Liu ZG, Han Y, Fan DM (2005). Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol, 11, 931-7.   DOI
7 Longworth MS, Laimins LA (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol Biol Rev, 68, 362-72.   DOI   ScienceOn
8 Mayrand MH, Duarte-Franco E, Rodrigues I, et al (2007). Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med, 357, 1579-88.   DOI   ScienceOn
9 Miller AB (1992). Cervical cancer screening programmes: managerial guidelines. Geneva: World Health Organization.
10 Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T (2004). The role of human papillomavirus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci, 50, 9-19.
11 Bharadwaj M, Hussain S, Nasare V, Das BC (2009). HPV & HPV vaccination: Issues in developing countries. Indian J Med Res, 130, 327-33.
12 Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74.   DOI
13 Sankaranarayanan R, Okkuru Esmy P, Rajkumar R, et al (2007). Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet, 370, 398-406.   DOI
14 Solomon D, Schiffman M, Tarone R (2001). Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst, 93, 293-99.   DOI   ScienceOn
15 Stamenkovic I (2000). Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol, 10, 415-33.   DOI   ScienceOn
16 Stoler MH (2001). HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J Histochem Cytochem, 49, 1197-8.   DOI
17 Villa LL, Costa RL, Pettac A, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8.   DOI   ScienceOn
18 Villa LL, Ault KA, Guiliano AR, et al (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24, 5571-83.   DOI
19 Villa LL, Costa RLR, Petta CA, et al (2007). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus like particle vaccine through 5 years follow-up. Br J Cancer, 6, 1459-66.
20 Villers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H (2004). Classification of papillomaviruses. Virology, 324, 17-27.   DOI   ScienceOn
21 Vizcaino AP, Moreno V, Bosch FX, et al (2000). International trends in incidence of cervical cancer: II. Squamous - cell carcinoma. Int J Cancer, 86, 429-35.   DOI   ScienceOn
22 Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.   DOI   ScienceOn
23 Zur Hausen H (1991). Viruses in human cancers. Science, 254, 1167-73.   DOI
24 Zur Hausen H (2002). Papillomaviruses and cervical cancer. Nat Rev, 2, 342-50.   DOI   ScienceOn
25 Bovicelli A, Bristow RE, Montz FJ (2000). HPV testing: where are we now? Anticancer Res, 20, 4673-80.
26 Bosch FX, Lorincz A, Munoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.   DOI
27 Bosch F (2003). Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex, 45, 326-39.
28 Bosch FX, Castellsague X, S de Sanjose (2008). HPV and cervical cancer: screening or vaccination? Br J Cancer, 98, 15-21.   DOI
29 Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101.   DOI
30 Dabash R, Vajpayee J, Jacob M, et al (2005). A strategic assessment of cervical cancer prevention and treatment services in 3 districts of Uttar Pradesh, India. Reprod Health, 2, 11.
31 Das BC, Hussain S, Nasare V, Bharadwaj M (2008). Prospects and prejudices of human papillomavirus vaccines in India. Vaccine, 26, 2669-79.   DOI
32 Denny L, Quinn M, Sankaranarayanan R (2006). Chapter 8: Screening for cervical cancer in developing countries. Vaccine, 24, 71-7.   DOI   ScienceOn
33 Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002 (2004). Cancer incidence, mortality and prevalence worldwide, version 2.0. IARC Cancer Base No. 5 Lyon, France: IARC Press.
34 Ganguly N, Parihar SP (2009). Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci, 34, 113-23.   DOI